Published • loading... • Updated
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SueWallSt said investors may face losses as Syndax shares fell 13% after the notice.
- On Tuesday, October 13, 2026, Syndax Pharmaceuticals shares opened down 11.72% after the company announced that axatilimab failed to meet the primary endpoint of its Phase 2 MAXPIRe trial in idiopathic pulmonary fibrosis .
- Chief Medical Officer Botwood described the study on February 26, 2026 as having the "potential to provide robust proof-of-concept data for axatilimab in IPF," expressing confidence in the trial's design and outcome.
- By midday on Tuesday, the stock had faltered by more than $2.50, or 15%, from the previous day's closing price. The 145-patient MAXPIRe trial measured the annualized rate of decline in forced vital capacity , a measure of lung function.
- Securities litigation firm Levi & Korsinsky LLP, operating as SueWallSt, announced a pending investigation into potential securities law violations on behalf of shareholders who suffered losses during the October 13 selloff.
- Eligibility for potential compensation depends on purchase dates and documented losses rather than whether shareholders still hold the stock, with no immediate action required for investors to participate.
Insights by Ground AI
21 Articles
21 Articles
The Logan Banner+20 Reposted by 20 other sources
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending investigation into potential securities law violations…
Coverage Details
Total News Sources21
Leaning Left1Leaning Right3Center14Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
C 78%
R 17%
Factuality
To view factuality data please Upgrade to Premium
